SciELO - Scientific Electronic Library Online

 
vol.103 número7¿Es posible predecir la infiltración de eosinófilos en la mucosa de una esofagitis eosinofílica sin realizar una endoscopia?Adenocarcinoma y linfoma gástricos sincrónicos índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista Española de Enfermedades Digestivas

versión impresa ISSN 1130-0108

Rev. esp. enferm. dig. vol.103 no.7 Madrid jul. 2011

https://dx.doi.org/10.4321/S1130-01082011000700014 

LETTERS TO THE EDITOR

 

Intestinal perforation due to cutaneous malignant melanoma mestastatic implants

Perforación intestinal por implantes metastásicos de melanoma maligno cutáneo

 

 


Key words: Small intestine. Intestinal perforation. Cutaneous malignant melanoma. Intestinal metastasis.

Palabras clave: Intestino delgado. Perforación intestinal. Melanoma maligno cutáneo. Metástasis intestinal.


 

Dear Editor,

Cutaneous malignant melanoma is the extra-abdominal neoplasia most frequently metastasized to the gastrointestinal tract. Although it can be located in any segment, it is most frequently established in the small intestine (51-71%), stomach (27%), large intestine (22%) and the oesophagus (5%). These metastases can occur synchronically with the primary tumour or appear decades later, as the first sign of a relapse of the disease in the form of: abdominal pain, dysphagia, intestinal obstruction, haematemesis, melaenas, etc. which require urgent surgery, justified by the improvement in the quality of life it provides with low morbidity and mortality (1).

The differential diagnosis between primary and metastatic intestinal malignant melanoma may be complicated with routine examinations such as a barium study and CT scan, as their sensitivity is limited. The Positron emission tomography, however, can improve the detection of melanoma metastasis to the gastrointestinal tract. Despite the different therapeutic strategies, surgical removal is considered to be the treatment of choice in patients with resectable metastatic intestinal malignant melanoma (2).

Prognosis is bad with an average survival rate of from 4 to 6 months (3), and is even worse in the case of primary intestinal malignant melanoma than when dealing with intestinal metastasis from extra-abdominal malignant melanoma (2).

We present the clinical case of a young man who has undergone surgery for multiple intestinal perforations secondary to cutaneous malignant melanoma metastatic implants.

 

Case report

Patient aged 23, with a history of resection of cutaneous melanoma and left axillary lymphadenectomy as a consequence of metastatic adenopathies of one year evolution, and "interferon" as adjuvant treatment. He was admitted to Oncology due to a severe vasogenic oedema and displacement of the midline secondary to unique cerebral metastasis in the left parietal lobe. During admission he presents a clinical picture of abdominal distension associated with pain and guarding of hypogastrium-RIF, the abdominal X-ray showing: distended loops of the small intestine and descending colon, an abdominal CT scan revealing pneumoperitoneum with free peritoneal liquid (Fig. 1). In the face of these findings he was submitted to urgent surgery, which revealed a generalized peritonitis secondary to perforation of the small intestine in 3 segments located in the proximal and distal jejunum, on the level of the distal ileum, related to cutaneous melanoma metastatic implants. Resection of the affected intestine was carried out. The postoperative evolution was satisfactory and the patient was discharged on the 10th day. The anatomopathological study confirmed the diagnosis of intestinal metastasis from cutaneous malignant melanoma (Fig. 2) The patient died at home, 5 months later, due to the progression of the disease.

 

Discussion

At present, metastatic melanoma is considered to be a practically incurable disease. The survival rate for patients with distant metastasis is 5-10% at 5 years and 2% at 15 years (4).

Gastrointestinal metastases from melanoma reflect an advanced stage of the disease, clinically undetectable in the initial phases. The diagnosis is normally carried out because of complications, which means that the principal aim of the treatment should be to palliate the latter (5).

Some series have shown increased survival in the group with complete resection of these lesions. Berger et al published a study of 50 patients with melanoma metastatic to the gastrointestinal tract, 37 of whom were submitted to surgical resection, those submitted to complete resection with a median survival of 23.5 months, compared with 8.9 months in patients submitted to partial resection (5,6).

Until only a few decades ago, the surgical treatment of metastatic melanoma was contemplated as a medical intervention which only makes any sense in the case of symptomatic metastases causing obstruction or haemorrhage. It is now known that the palliative surgical removal of unique metastases implies a significant lengthening of disease free time, with the consequent increase in quality of life (4).

 

Rocío González-López, Paula Montoto-Santomé, Eva Iglesias-Porto, María Isabel Pérez-Moreiras,
Carlos Gegúndez-Gómez, José Manuel Couselo-Villanueva, Marlén Alvite-Canosa, Olga Robles-Veiga,
Ana Elisa Álvarez-Gutiérrez, Inmaculada Monjero-Ares and Félix Arija-Val

Department of General and Digestive Surgery. Complejo Hospitalario Xeral Calde de Lugo. Lugo, Spain

 

References

1. Gordón Suárez A, Sánchez Ganfornina A, López Ruíz J, Baez Romero Francisco. Intususcepción yeyunal por metástasis de melanoma cutáneo. Cir Esp 2008;84:174-5.         [ Links ]

2. Lens M, Bataille V, Krivokapic Z. Melanoma of the small intestine. Lancet Oncology 2009;10(5):516-21.         [ Links ]

3. Liang KV, Sanderson SO, Nowakowski GS, Arora AS. Metastatic malignant melanoma of the gastrointestinal tract. Mayo Clin Proc 2006;81 (4):511-6.         [ Links ]

4. Martí Rosa M, Grupo Melanoma IDIBAPS. Tratamiento del melanoma metastásico. Piel 2003;18: 216-28.         [ Links ]

5. Berger AC, Buell JF, Venzon D, Baker AR, Libutti SK. Management of symptomatic malignant melanoma of the gastrointestinal tract. Ann Surg Oncol 1999; 6(2):155-60.         [ Links ]

6. Petrovic M, Popovic M, Matic S, et al. Metastasis of malignant melanoma in the small intestine-case report. Acta Chir Iugosl 2000;47(1-2):97-101.         [ Links ]

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons